Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EN006
- Development stage
- Preclinical
- Lead developer
- Letolab
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
EN006 is a recombinant Factor VIIa biosimilar being developed by Letolab for the treatment of Hemophilia A and Hemophilia B. As a biosimilar to recombinant Factor VIIa products (such as eptacog alfa), it is designed to promote coagulation and control bleeding episodes in patients with hemophilia, particularly those who have developed inhibitors to Factor VIII or IX. The drug works by activating the extrinsic pathway of the coagulation cascade, bypassing the need for Factor VIII or IX to generate thrombin. EN006 is currently in the lead optimization phase of preclinical development.
- Other names
- Factor VIIa biosimilarrecombinant Factor VIIa biosimilar
02
Targets
Tissue factor/factor viia complex
Beyond the preview
Go deeper on EN006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EN006.